A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025- -Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and...
Conference Call Scheduled for Thursday, May 23, 2024 at 8:30 AM ET.DUBLIN, Ireland, May 21, 2024 -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including...
DUBLIN, Ireland, May 16, 2024 -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical...
DUBLIN, Ireland, May 13, 2024 -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional...
DUBLIN, Ireland, May 08, 2024 -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous...
DUBLIN, Ireland, April 04, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31,...
Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ETDUBLIN, Ireland, March 28, 2024 -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory...
DUBLIN, Ireland, March 08, 2024 -- Trinity Biotech Plc. (NASDAQ: TRIB) (the "Company") today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(a)(1), which requires...
DUBLIN, Ireland, Feb. 15, 2024 -- Trinity Biotech Plc.(NASDAQ: TRIB) (the "Company") today announced that it has finalized the effective date of its ratio change of its American depositary shares ("ADSs") from one (1) ADS representing four (4) Class A ordinary shares...
DUBLIN, Ireland, Feb. 13, 2024 -- Trinity Biotech Plc.(NASDAQ: TRIB) (the "Company") today announced that it plans to change the ratio of the American depositary shares ("ADSs") representing its Class A ordinary shares from one (1) ADS representing four (4) Class A...